

Amber with Guidance (Amber-G) = To be recommended or initiated by a specialist* with follow up prescribing and monitoring by primary care clinicians.

*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme, or who has the appropriate knowledge and competencies within the described area of practice.

Sucralfate 1g/5ml oral suspension sugar-free (SF) for benign gastric ulceration, benign duodenal ulceration, chronic gastritis, prophylaxis of stress ulceration in adults.

The details of side-effects, cautions, contraindications and interactions are not a complete list and the current BNF (<https://www.medicinescomplete.com/#/>) remains authoritative. *At the time of writing no SPC was available.*

| | |
|---|---|
| Background Information¹ | <p>Sucralfate oral suspension was previously only available as an unlicensed special. A licensed sucralfate 1g/5ml oral suspension sugar-free is now available. Sucralfate 1g/5ml oral suspension sugar-free is to be recommended or initiated by a specialist with follow up prescribing and monitoring by primary care clinicians.</p> <p>Do not prescribe unlicensed sucralfate liquid preparations Do not prescribe sucralfate tablets (unlicensed)</p> |
| BNF therapeutic class¹ | <p>1.4.2 Gastro-intestinal system/Disorders of gastric acid and ulceration/Gastric and duodenal ulceration/Chelates and complexes.</p> |
| Indication¹ | <ul style="list-style-type: none"> Sucralfate is a complex of aluminium hydroxide and sulfated sucrose which forms a barrier to protect the mucosa from acid, pepsin and bile attack in gastric and duodenal ulcers. Sucralfate 1g/5ml oral suspension SF is licenced for benign gastric ulceration, benign duodenal ulceration, chronic gastritis and prophylaxis of stress ulceration in adults. |
| Dosage and administration¹ | <ul style="list-style-type: none"> Benign gastric ulceration and benign duodenal ulceration; dose by mouth: Adults: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day. Chronic gastritis; dose by mouth: Adults: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day. Prophylaxis of stress ulceration; dose by mouth: Adults: 1 g 6 times a day; maximum 8 g per day Sucralfate oral suspension 1g/5ml SF is available as a 200ml bottle. To be given 1 hour before meals. Separate co-administration with enteral feeds by 1 hour. Oral suspension blocks fine-bore feeding tubes, refer to NEWT guidelines for further information. |
| Cautions and Contraindications^{1,2} | <p>Contraindications</p> <ul style="list-style-type: none"> Hypersensitivity to sucralfate or any of the other ingredients of Sucralfate 1g/5ml Oral Suspension SF.² Patient is on dialysis.² <p>Cautions</p> <ul style="list-style-type: none"> Patients under intensive care: Bezoar* formation: Following reports of bezoar* formation associated with sucralfate, caution is advised in seriously ill patients, |

Amber with Guidance (Amber-G) = To be recommended or initiated by a specialist* with follow up prescribing and monitoring by primary care clinicians.

*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme, or who has the appropriate knowledge and competencies within the described area of practice.

| | |
|---|---|
| | <p>especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying</p> <ul style="list-style-type: none"> Renal impairment: Should be used with caution in patients with renal impairment due to potential accumulation of aluminium. Contains hydroxybenzoates. May cause allergic reactions and delayed allergic reactions.² |
| Pregnancy and breast feeding¹ | <ul style="list-style-type: none"> Pregnancy - No evidence of harm; absorption from gastro-intestinal tract negligible. Breast feeding - Amount probably too small to be harmful. |
| Adverse Drug Reactions¹ | <ul style="list-style-type: none"> Common – constipation; uncommon – dry mouth, nausea; rare/very rare – bezoar* formation, rash. Any serious adverse reactions should be reported to the MHRA via the Yellow Card scheme: www.mhra.gov.uk/yellowcard |
| Monitoring | <ul style="list-style-type: none"> No specific therapeutic monitoring is recommended for sucralfate. |
| Interactions^{1,2,3} | <ul style="list-style-type: none"> Sucralfate may decrease the gastrointestinal absorption of furosemide (take the drugs at least 2 hours apart). Sucralfate decreases the absorption of Digoxin. Manufacturer advises separate administration by 2 hours. Due to the potential of sucralfate to decrease absorption of other medicines the manufacturer of sucralfate 1g/5ml oral suspension SF recommends leaving a two hour gap between taking sucralfate oral suspension and the other medicine. For "antacid" medicines, the gap should be at least half an hour.² Consult the BNF for further information. |
| Ordering information⁴ | <ul style="list-style-type: none"> Do not prescribe unlicensed sucralfate liquid preparations. Please ensure correct product selection on primary care clinical systems. At the time of writing AAH and Sigma supply the licensed sucralfate 1g/5ml oral suspension SF. |

*A bezoar is a tightly packed collection of partially digested or undigested material that most commonly occurs in the stomach. Gastric bezoars can occur in all age groups and often occur in patients with behaviour disorders, abnormal gastric emptying, or altered gastrointestinal anatomy. Many bezoars are asymptomatic, but some cause symptoms. Some bezoars can be dissolved chemically, others require endoscopic removal, and some even require surgery.

Contact names and details

| Contact Details | Telephone number | Email |
|---|------------------------------|--|
| Dr K Kapur, Consultant Gastroenterologist | 01226 432542 01226 432715 | kapil.kapur@nhs.net |
| Dr A Soliman, Consultant Gastroenterologist | 01226 432542 01226 432715 | a.soliman@nhs.net |
| Dr D Bullas, Consultant Gastroenterologist | 01226 432542 01226 432715 | dominicbullas@nhs.net |
| Dr V Sathyanarayan, Consultant Gastroenterologist | 01226 432542 01226 432715 | vsathyanarayana@nhs.net |
| Dr N Sundar, Consultant Gastroenterologist | 01226 432542 01226 432715 | neela.sundar@nhs.net |
| Dr E Said, Consultant Gastroenterologist | 01226 432542 01226 432715 | elmuhtady.said@nhs.net |
| Dr R Atkinson, Consultant Gastroenterologist | 01226 432542 01226 432715 | r.atkinson3@nhs.net |
| Dr Shirazi-Nejad, Consultant Gastroenterologist | 01226 432542 01226 432715 | a.shirazi-nejad1@nhs.net |
| Gillian Turrell, Medicines Information BHNFT | 01226 432857 | gilliansmith2@nhs.net |

Sucralfate 1g/5ml oral suspension SF Amber-G Guideline

Amber with Guidance (Amber-G) = To be recommended or initiated by a specialist* with follow up prescribing and monitoring by primary care clinicians.

*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme, or who has the appropriate knowledge and competencies within the described area of practice.

- BHNFT Gastroenterology Department: <https://www.barnsleyhospital.nhs.uk/service/gastroenterology/>

References

1. British National Formulary (BNF). Available from: <https://bnf.nice.org.uk/drugs/sucralfate/> Accessed 30/05/2022
2. Medicines and Healthcare Products Regulatory Agency (MHRA). Patient Information Leaflet. 2021. Antepsin Suspension® 1g/5ml. Available from: <https://products.mhra.gov.uk/product/?product=ANTEPSIN%201G%2F5ML%20ORAL%20SUSPENSION%2C%20SUCRALFATE%201G%2F5ML%20ORAL%20SUSPENSION> Accessed 13/06/2022
3. National Institute of Clinical Excellence (NICE) Clinical Knowledge Summaries. 2022. Managing Diuretics. Available from: <https://cks.nice.org.uk/topics/heart-failure-chronic/prescribing-information/managing-diuretics/> Accessed 13/06/2022
4. NHS dm+d browser. Available from: <https://services.nhsbsa.nhs.uk/dmd-browser/vmp/view/2174/suppliers?ref=YW1wTmFtZT1zdWNyYWxmYXRlK3N1c3BlbnNpb24mc2VhcmNoVHlwZT1BTVAmc2hvd0ludmFsaWRJdGVtcz1mYWxzZSZoaWRlUGFyYWxsZWxJbXBvcnQ9ZmFsc2UmaGlkZVNwZWNPYWxPcmRlcj1mYWxzZSZoaWRlRGlzY29udGludWVWkSXRlbXM9ZmFsc2U%3D> Accessed 7/11/2022

Development Process

This guidance has been produced following an AMBER-G classification status of sucralfate 1g/5ml oral suspension SF by the Barnsley Area Prescribing Committee. This guideline has been subject to consultation and endorsement by the gastroenterologists and was ratified by the Area Prescribing Committee on 14th December 2022.